```html

Steven‑Johnson Syndrome (SJS) – A Complete Patient Guide

Overview

Steven‑Johnson Syndrome (SJS) is a rare, life‑threatening disorder that affects the skin and mucous membranes. It is considered a severe form of a spectrum of conditions called toxic epidermal necrolysis (TEN). While SJS typically involves <10 % of the body surface area (BSA), TEN involves >30 % and the overlap (10‑30 %) is sometimes called SJS/TEN.

Who it affects: SJS can occur at any age, but the highest incidence is seen in adults aged 30‑50 years. Children can be affected, especially after exposure to certain antibiotics. Women are slightly more likely to develop SJS than men (approximately 1.2‑to‑1 ratio).

Prevalence: The worldwide incidence is estimated at 1–6 cases per million people per year. In the United States, CDC reports roughly 2 cases per million annually, translating to about 600–800 new cases each year.

Because the disease progresses quickly and can involve multiple organ systems, early recognition and treatment are critical.

Symptoms

The hallmark of SJS is a rapid onset of painful skin and mucosal lesions. Below is a comprehensive list of typical signs and how they evolve.

Early (Prodromal) Symptoms – 1‑3 days

• Fever – often >38 °C (100.4 °F).
• Flu‑like symptoms – sore throat, cough, headache, malaise.
• Conjunctival redness – itching or burning eyes.
• Upper respiratory or gastrointestinal upset – nausea, vomiting, abdominal pain.

Skin Manifestations – 2‑5 days after prodrome

• Target (iris) lesions – round, dusky central area surrounded by a paler ring and a peripheral erythematous halo; usually <5 mm in diameter.
• Macules and papules – flat or raised red spots that may coalesce.
• Blistering and epidermal detachment – the skin becomes thin and may slough off, exposing raw dermis.
• Positive Nikolsky sign – gentle pressure on normal‑appearing skin causes it to peel away.
• Distribution – commonly starts on the face and trunk, then spreads to extremities.

Mucosal Involvement

• Oral cavity – painful erosions, crusting of lips, difficulty swallowing.
• Ocular – conjunctivitis, photophobia, possible ulceration of the cornea.
• Genital – painful erosions of the vulva or penis, urinary discomfort.
• Respiratory & gastrointestinal mucosa – rare but can cause airway obstruction or bleeding.

Systemic Signs

• Dehydration from fluid loss.
• Electrolyte abnormalities.
• Acute kidney injury.
• Hepatic dysfunction.

Symptoms typically peak within one week and can improve within 2‑3 weeks with appropriate care, but scarring and sequelae may persist.

Causes and Risk Factors

SJS is most often an adverse reaction to a medication, but infections and other triggers have also been documented.

Medications – the leading cause (≈70‑95 % of cases)

• Antibiotics – especially sulfonamides (e.g., trimethoprim‑sulfamethoxazole), fluoroquinolones, and β‑lactams.
• Antiepileptics – carbamazepine, lamotrigine, phenytoin, phenobarbital.
• Allopurinol – frequently implicated in adults.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – particularly oxicam derivatives.
• Contrast agents used in imaging studies.

Infections

• Herpes simplex virus (HSV) – most common infectious trigger in children.
• Mycoplasma pneumoniae.
• Hepatitis viruses, HIV, and others.

Other Risk Factors

• Genetic predisposition – HLA‑B*1502 in Asian populations increases risk with carbamazepine (CDC recommendation).
• Previous drug reaction – history of a milder rash may herald severe SJS.
• Immunocompromised state – HIV infection, organ transplantation.
• Age – children are more prone to infection‑triggered SJS; older adults to medication‑triggered SJS.

Diagnosis

Diagnosis is primarily clinical but must be confirmed and staged to guide management.

Clinical Assessment

• Detailed history of medication use (including over‑the‑counter drugs and herbal supplements) within the past 4 weeks.
• Physical examination documenting skin lesions, BSA involvement, and mucosal sites.
• Assessment of vital signs and organ function (renal, hepatic, pulmonary).

Scoring Systems

• SCORTEN – a severity‑of‑illness score (7 variables) that predicts mortality; each positive variable adds 1 point (e.g., age > 40 y, heart rate > 120 bpm, BSA > 10 %).

Laboratory Tests

• Complete blood count (CBC) – may show leukocytosis or eosinophilia.
• Comprehensive metabolic panel – assesses electrolytes, renal and liver function.
• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – markers of inflammation.
• Viral PCR or serology if infection suspected.

Skin Biopsy

A 4‑mm punch biopsy showing full‑thickness epidermal necrosis with minimal inflammatory infiltrate confirms SJS and helps rule out mimickers such as staphylococcal scalded skin syndrome or erythema multiforme.

Imaging (if needed)

• Chest X‑ray or CT for pulmonary involvement.
• Abdominal ultrasound if liver involvement is suspected.

Treatment Options

SJS is a medical emergency. Early withdrawal of the offending agent and supportive care in a specialized unit (burn ICU or dermatology ward) are the cornerstones.

Immediate Measures

• Discontinue the suspected drug immediately—do not wait for test results.
• Begin fluid resuscitation guided by burn protocols (e.g., 4 mL/kg/%BSA over 24 h).
• Provide pain control – intravenous opioids are often required.
• Maintain a sterile wound environment – use non‑adhesive dressings, avoid debridement unless necrotic tissue is extensive.

Pharmacologic Therapies

• Corticosteroids – high‑dose IV methylprednisolone (1–2 mg/kg/day) is controversial but may be useful early in disease (<48 h). Evidence is mixed; see Lancet Haematology 2020.
• Intravenous Immunoglobulin (IVIG) – doses 2 g/kg over 2‑4 days; may block Fas‑mediated keratinocyte apoptosis. Some studies suggest benefit in patients with SCORTEN ≥ 3.
• Ciclosporin – 3 mg/kg/day oral or IV; recent meta‑analysis (Cleveland Clinic 2022) shows reduced mortality and faster re‑epithelialization.
• TNF‑α inhibitors (e.g., etanercept) – emerging evidence from small RCTs suggests faster skin healing.
• Antibiotics – only for documented bacterial infection; prophylactic use is discouraged because of resistance risk.

Supportive Care

• Temperature regulation – use cooling blankets; avoid overheating.
• Nutrition – enteral feeding (tube if oral intake impossible) to meet >30 kcal/kg/day.
• Ophthalmology consultation – early use of lubricating eye drops, topical steroids, and, if needed, amniotic membrane transplantation.
• Physical therapy – to preserve range of motion and prevent contractures.

Procedures

• Wound care – gentle debridement, biosynthetic dressings (e.g., porcine small intestinal submucosa) or negative‑pressure wound therapy in select cases.
• Dialysis – for severe renal failure or fluid overload.

Living with Steven‑Johnson Syndrome

Even after discharge, many patients experience long‑term sequelae. Below are actionable tips for daily life.

Skin Care

• Use fragrance‑free, hypoallergenic moisturizers multiple times daily.
• Avoid tight clothing, wool, or rough fabrics that can irritate healing skin.
• Protect new skin from sun exposure; apply broad‑spectrum SPF 30+ sunscreen.

Eye Care

• Artificial tears at least 4–6 times per day.
• Wear protective sunglasses outdoors.
• Follow up with an ophthalmologist every 3‑6 months for the first year.

Mucosal Health

• Stay hydrated; sip water or oral rehydration solutions.
• Use bland, non‑irritating oral rinses (e.g., saline or sodium bicarbonate).
• Report persistent oral pain, swallowing difficulty, or new ulcerations.

Psychological Support

• Consider counseling or support groups—SJS can cause anxiety, depression, and PTSD.
• Mind‑body techniques (deep breathing, guided imagery) can aid coping.

Follow‑up Schedule

• Dermatology: every 2‑4 weeks initially, then spaced out as healing progresses.
• Primary care: at least once a month for the first 3 months, then per physician recommendation.
• Specialists (ophthalmology, urology, pulmonology) as indicated by lingering symptoms.

Prevention

Because the most common trigger is medication, prevention focuses on careful drug prescribing and patient awareness.

• Medication review – before starting high‑risk drugs, clinicians should assess prior drug reactions and, when appropriate, order HLA‑B*1502 testing (especially in individuals of Asian descent).
• Patient education – provide written lists of drugs to avoid and emergency instructions.
• Allergy cards – carry a medical alert card stating “Steven‑Johnson Syndrome – avoid sulfonamides, carbamazepine, allopurinol, etc.”
• Vaccination – up‑to‑date immunizations (e.g., influenza, COVID‑19) reduce infection‑related triggers.
• Prompt reporting – seek medical help at the first sign of a rash after a new medication.

Complications

If not treated promptly, SJS can lead to severe, sometimes permanent, complications.

• Secondary infections – bacterial sepsis is the leading cause of mortality.
• Ocular sequelae – symblepharon, cataracts, corneal scarring, and vision loss in up to 30 % of survivors.
• Scar contractures – especially around joints, leading to limited mobility.
• Genital adhesions – may cause urinary obstruction or sexual dysfunction.
• Chronic pain and neuropathy – due to nerve damage in affected skin.
• Psychological impact – depression, anxiety, and post‑traumatic stress disorder.
• Organ dysfunction – renal failure, hepatic injury, or pulmonary complications.

When to Seek Emergency Care

References

• Mayo Clinic. Stevens‑Johnson syndrome and toxic epidermal necrolysis. https://www.mayoclinic.org
• CDC. Stevens‑Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) – Data & Statistics. https://www.cdc.gov
• World Health Organization. WHO drug safety alerts – Stevens‑Johnson syndrome. https://www.who.int
• Cleveland Clinic. Stevens‑Johnson syndrome: Treatment and prognosis. https://my.clevelandclinic.org
• Huang et al. Cyclosporine versus IVIG for SJS/TEN: A systematic review. *J Dermatol Ther* 2022.
• Gelfand et al. SCORTEN: A severity‑of‑illness score for toxic epidermal necrolysis. *J Invest Dermatol* 2000.
• United States Food and Drug Administration. Drug Safety Communication: HLA‑B*1502 testing for carbamazepine. 2023.

```